Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in.

Published byΝικηφόρος Μήτζου Modified over 4 years ago

Similar presentations

Presentation on theme: "Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in."— Presentation transcript:

1 Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate.
Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Serum bicarbonate (A), serum potassium (B), systolic and diastolic BP (C), and body weight (D) in relation to dose of oral sodium bicarbonate. P values were calculated using mixed-effects models separately examining the association of sodium bicarbonate dose with repeated measurements of each outcome. Matthew K. Abramowitz et al. CJASN 2013;8: ©2013 by American Society of Nephrology

Download ppt "Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in."

Similar presentations

Relationship between serum sodium after racing and the weight change (in %) during exercise in 2135 athletes who competed in endurance events. •, asymptomatic.

Relationship between serum sodium after racing and the weight change (in %) during exercise in 2135 athletes who competed in endurance events. •, asymptomatic.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Adjusted all-cause mortality risk by dialysate sodium (DNa) and predialysis serum sodium (SNa). Adjusted all-cause mortality risk by dialysate sodium (DNa)

Adjusted all-cause mortality risk by dialysate sodium (DNa) and predialysis serum sodium (SNa). Adjusted all-cause mortality risk by dialysate sodium (DNa)
Differing renal outcomes associated with AKI electronic alerts for clinical location of AKI subsets. Differing renal outcomes associated with AKI electronic.

Differing renal outcomes associated with AKI electronic alerts for clinical location of AKI subsets. Differing renal outcomes associated with AKI electronic.
American Journal of Kidney Diseases

American Journal of Kidney Diseases
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.
Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.
ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.

ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.
Receiver operating characteristic curves of prediction models.

Receiver operating characteristic curves of prediction models.
Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%

Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)
A glomerulus from a patient who developed nephrotic syndrome while receiving a nonsteroidal anti-inflammatory drug for arthritis. A glomerulus from a patient.

A glomerulus from a patient who developed nephrotic syndrome while receiving a nonsteroidal anti-inflammatory drug for arthritis. A glomerulus from a patient.

Similar presentations

Ads by Google